ImmunoPrecise (NASDAQ:IPA) Reports $19.4 million Record Revenues of for Full Fiscal Year 2022 Dually Listed Co’s THRM.V/TBRIF, RFR.C/RFHRF, SFET/SFET.TA, AMY.V/AMYZF, GEMS.C / TLOOF

July 29, 2022

IPA/IMMUNOPRECISE ANTIBODIES LTD. – (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for the full fiscal year 2022 ended April 30, 2022. The Company achieved record revenues of $19.4 million, up 8.1% from $17.9 million in the fiscal year 2021 The Company achieved record revenues of $5.2 million for the three months ended April 30, 2022, an increase of 7.4% over the same…

Read More >>